Effect of Covid-19 on Hypertension

Sponsor

Shiraz University of Medical Sciences (Other)

Overall Status

Completed

CT.gov ID

NCT05798208

Collaborator

(none)

5,355

Enrollment

Locations

36.2

Actual Duration (Months)

1785

Patients Per Site

49.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this single center , retrospective study, 5355 covid patient were selected from 2020 to 2022, with recorded blood pressure before covid and recording after covid. Blood pressure before and after covid were compared, by pair T test.

Condition or Disease	Intervention/Treatment	Phase
COVID-19 Hypertension	Diagnostic Test: blood pressure measurement

Detailed Description

design and participants This single-center retrospective cohort study was conducted at an outpatient cardiology clinic in Shiraz, Iran, between February 15, 2020, and December 28, 2022. We evaluated patients with a confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by RNA reverse-transcriptase polymerase-chain-reaction assays from nasopharyngeal or oropharyngeal swab specimens according to World Health Organization guidelines (12). Two physicians (PA, MY) reviewed the patients' electronic medical records, including demographics, comorbidities, vital signs, treatments, and outcomes. Ambiguities were resolved by a third author (MM).

The current study included all COVID-19 patients who had at least one documented blood pressure measurement in the three months preceding infection and one documented measurement one to three months following recovery. The following patients were excluded: those under 18, with hospital admission due to COVID-19, who received corticosteroid therapy, those with a history of systemic inflammatory disease, kidney or liver, immunocompromised patients, and those who switched their antihypertensive regimen during the study. Finally, 5,355 eligible patients were investigated . The primary outcome was to assess BP variation following infection (particularly a prolonged rise in BP) among non-hospitalized COVID-19 patients. The secondary outcome was to identify the predictor factors of BP variation.

The present study was approved by the Ethics Committee of Shiraz University of Medical Sciences under code IR.SUMS.MED.REC.1401.465 , and the need for informed consent was waived due to the study's retrospective nature and the absence of patient identifiers in the presented data.

Study Design

Study Type:

Observational

Actual Enrollment :

5355 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

The Long-term Impact of COVID-19 on Blood Pressure: A Retrospective Cohort Study

Actual Study Start Date :

Feb 15, 2020

Actual Primary Completion Date :

Dec 28, 2022

Actual Study Completion Date :

Feb 20, 2023

Arms and Interventions

Arm	Intervention/Treatment
hypertensive Covid patients with exacerbated hypertension or new hypertension post covid	Diagnostic Test: blood pressure measurement Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
non hypertensive Covid patients with no change in blood pressure pre and post covid	Diagnostic Test: blood pressure measurement Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal

Arm

Intervention/Treatment

hypertensive

Covid patients with exacerbated hypertension or new hypertension post covid

Diagnostic Test: blood pressure measurement

Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal

non hypertensive

Covid patients with no change in blood pressure pre and post covid

Diagnostic Test: blood pressure measurement

Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal

Outcome Measures

Primary Outcome Measures

change of blood pressure [2 years]
any change in blood pressure level before and after covid infection

Secondary Outcome Measures

predictors of changes in blood pressure [2 years]
history of any risk factor for cardiac disease, age, sex,

Eligibility Criteria

Criteria

Ages Eligible for Study:

39 Years to 71 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

All COVID-19 patients who had at least one documented blood pressure measurement in the three months preceding infection and one documented measurement one to three months following recovery

Exclusion Criteria:

Age under 18
Hospital admission due to COVID-19
Corticosteroid therapy,
History of systemic inflammatory disease
kidney disease
liver disease
Immunocompromised patients

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cardiology Ward Shiraz University of Medical Sciences	Shiraz	Fars	Iran, Islamic Republic of	51318
2	Education Developmen Center	Shiraz	Fars	Iran, Islamic Republic of	55318
3	Professor kojuri cardiology clinic	Shiraz	Outside Of The US	Iran, Islamic Republic of	55318

Sponsors and Collaborators

Shiraz University of Medical Sciences

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Javad Kojuri, professor, Shiraz University of Medical Sciences

ClinicalTrials.gov Identifier:

NCT05798208

Other Study ID Numbers:

IR.SUMS.MED.REC.1401

First Posted:

Apr 4, 2023

Last Update Posted:

Apr 4, 2023

Last Verified:

Apr 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Javad Kojuri, professor, Shiraz University of Medical Sciences

covid-19

hypertension

blood pressure

Additional relevant MeSH terms:

COVID-19

Hypertension

Study Results

No Results Posted as of Apr 4, 2023